184 related articles for article (PubMed ID: 34558098)
21. Oxidative Stress in Patients with X-Linked Adrenoleukodystrophy.
Deon M; Marchetti DP; Donida B; Wajner M; Vargas C
Cell Mol Neurobiol; 2016 May; 36(4):497-512. PubMed ID: 26169524
[TBL] [Abstract][Full Text] [Related]
22. Thermogenic flux induced by lignoceric acid in peroxisomes isolated from HepG2 cells and from X-adrenoleukodystrophy and control fibroblasts.
Petroni A; Paroni R; Aloisi AM; Blasevich M; Haman N; Fessas D
J Cell Physiol; 2019 Aug; 234(10):18344-18348. PubMed ID: 30932193
[TBL] [Abstract][Full Text] [Related]
23. New Therapeutic Uses for Existing Drugs.
Austin BA; Gadhia AD
Adv Exp Med Biol; 2017; 1031():233-247. PubMed ID: 29214576
[TBL] [Abstract][Full Text] [Related]
24. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Baarine M; Beeson C; Singh A; Singh I
J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of retinoids for induction of the redundant gene ABCD2 as an alternative treatment option in X-linked adrenoleukodystrophy.
Weber FD; Weinhofer I; Einwich A; Forss-Petter S; Muneer Z; Maier H; Weber WH; Berger J
PLoS One; 2014; 9(7):e103742. PubMed ID: 25079382
[TBL] [Abstract][Full Text] [Related]
26. The clinical spectrum of X-linked adrenoleukodystrophy: from Addison's-only in men to middle-age neurologic manifestations in women.
Fadiga L; Melo M; Saraiva J; Paiva I
Hormones (Athens); 2022 Mar; 21(1):33-40. PubMed ID: 34652632
[TBL] [Abstract][Full Text] [Related]
27. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.
Kemp S; Huffnagel IC; Linthorst GE; Wanders RJ; Engelen M
Nat Rev Endocrinol; 2016 Oct; 12(10):606-15. PubMed ID: 27312864
[TBL] [Abstract][Full Text] [Related]
28. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.
Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP
J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896
[TBL] [Abstract][Full Text] [Related]
29. Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy.
Hjartarson HT; Ehrstedt C; Tedroff K
Eur J Paediatr Neurol; 2018 Jan; 22(1):178-181. PubMed ID: 28964670
[TBL] [Abstract][Full Text] [Related]
30. Childhood X-linked adrenoleukodystrophy: clinical-pathologic overview and MR imaging manifestations at initial evaluation and follow-up.
Kim JH; Kim HJ
Radiographics; 2005; 25(3):619-31. PubMed ID: 15888613
[TBL] [Abstract][Full Text] [Related]
31. X-linked adrenoleukodystrophy: genes, mutations, and phenotypes.
Smith KD; Kemp S; Braiterman LT; Lu JF; Wei HM; Geraghty M; Stetten G; Bergin JS; Pevsner J; Watkins PA
Neurochem Res; 1999 Apr; 24(4):521-35. PubMed ID: 10227685
[TBL] [Abstract][Full Text] [Related]
32. Failure of repeated cyclophosphamide pulse therapy in childhood cerebral X-linked adrenoleukodystrophy.
Horvath GA; Eichler F; Poskitt K; Stockler-Ipsiroglu S
Neuropediatrics; 2012 Feb; 43(1):48-52. PubMed ID: 22430161
[TBL] [Abstract][Full Text] [Related]
33. [Peroxisomal ABC transporters and X-linked adrenoleukodystrophy].
Geillon F; Trompier D; Gondcaille C; Lizard G; Savary S
Med Sci (Paris); 2012 Dec; 28(12):1087-94. PubMed ID: 23290409
[TBL] [Abstract][Full Text] [Related]
34. Drug repositioning for rare diseases: Knowledge-based success stories.
Scherman D; Fetro C
Therapie; 2020 Apr; 75(2):161-167. PubMed ID: 32164975
[TBL] [Abstract][Full Text] [Related]
35. Chinese patients with adrenoleukodystrophy and Zellweger spectrum disorder presenting with hereditary spastic paraplegia.
Chen YJ; Wang MW; Dong EL; Lin XH; Wang N; Zhang ZQ; Lin X; Chen WJ
Parkinsonism Relat Disord; 2019 Aug; 65():256-260. PubMed ID: 31227335
[TBL] [Abstract][Full Text] [Related]
36. Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: implications for gene therapy of X-linked adrenoleukodystrophy.
Unterrainer G; Molzer B; Forss-Petter S; Berger J
Hum Mol Genet; 2000 Nov; 9(18):2609-16. PubMed ID: 11063720
[TBL] [Abstract][Full Text] [Related]
37. Rolipram does not normalize very long-chain fatty acid levels in adrenoleukodystrophy protein-deficient fibroblasts and mice.
Netik A; Hobel A; Rauschka H; Molzer B; Forss-Petter S; Berger J
J Inherit Metab Dis; 2000 Sep; 23(6):615-24. PubMed ID: 11032336
[TBL] [Abstract][Full Text] [Related]
38. Cyclophilin D as a potential target for antioxidants in neurodegeneration: the X-ALD case.
López-Erauskin J; Ferrer I; Galea E; Pujol A
Biol Chem; 2013 May; 394(5):621-9. PubMed ID: 23492556
[TBL] [Abstract][Full Text] [Related]
39. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.
Engelen M; Kemp S; de Visser M; van Geel BM; Wanders RJ; Aubourg P; Poll-The BT
Orphanet J Rare Dis; 2012 Aug; 7():51. PubMed ID: 22889154
[TBL] [Abstract][Full Text] [Related]
40. A Literature-Based Knowledge Graph Embedding Method for Identifying Drug Repurposing Opportunities in Rare Diseases.
Sosa DN; Derry A; Guo M; Wei E; Brinton C; Altman RB
Pac Symp Biocomput; 2020; 25():463-474. PubMed ID: 31797619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
